GlobeNewsWire
02 Oct 2026, 13:43 UTC · 4h ago
Verdict
Headline takes no side. We score ICU +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
SeaStar Medical will present post-approval SAVE Registry data for its SCD-PED device at ASN Kidney Week 2026 on October 22.
Newannounced today, Oct. 02, 2026
More positive than 79% of claims this week
The company is conducting the NEUTRALIZE-AKI pivotal clinical trial for adult patients with AKI requiring continuous renal replacement therapy.
Priced in
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
So whatExpanding the SCD therapy to the 200,000 annual adult U.S. patient population would represent a massive increase in Total Addressable Market (TAM) compared to the ultra-rare pediatric niche.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company announced a late-breaking presentation of positive registry data at a major medical conference.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
6h ago
+0.1%
Price flat so far
$3.75 vs $3.75 close before publication (Oct 1) · not market-adjusted
ICU chart →
